NCT05075993View on ClinicalTrials.gov

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions
Metastatic EsophagealGastric CancerMetastatic Head and Neck CarcinomaMetastatic Hepatocellular CarcinomaMetastatic HPV Related Solid TumorsMetastatic Ovarian CarcinomaMetastatic Soft Tissue SarcomaMetastatic Uveal Melanoma
Interventions
DRUG

LVGN3616 + LVGN6051 + Nab-Paclitaxel

Given by IV, Given by PO

DRUG

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide

Given by IV, Given by PO

DRUG

LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel

Given by IV, Given by PO

DRUG

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide

Given by IV, Given by PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Lyvgen Biopharma Holdings Limited

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER